Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
Japanese drugmaker Astellas Pharma Inc (4503.T) is looking to sell its dermatology portfolio, which could be worth between $500 million and $1 billion, according to three people familiar with the situation. Astellas has hired London-based investment banking boutique DC Advisory to sell the assets, according to two of the people, who wished to remain anonymous because they are not permitted to speak to the press. The company’s dermatology portfolio, which includes a drug to treat eczema called Protopic, sells products around the world.
Help employers find you! Check out all the jobs and post your resume.
